MRD in CLL

CE / CME

Assessing Measurable Residual Disease in Chronic Lymphocytic Leukemia

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: August 30, 2022

Expiration: August 29, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Anthony J Perissinotti
Anthony J Perissinotti, PharmD, BCOP
Jennifer A. Woyach
Jennifer A. Woyach, MD

Activity

Progress
1
Course Completed

References

  1. Fürstenau M, De Silva N, Eichhorst B, et al. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere. 2019;3:e287.
  2. Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929-936.
  3. Raponi S, Della Starza I, De Propris MS, et al. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol. 2014;166:360-368.
  4. US Food and Drug Administration. FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma. fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer. Accessed August 23, 2022.
  5. Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303-309.
  6. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208-215.
  7. Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269-277.
  8. Kater AP, Qu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042-4054.
  9. Al-Sawaf O, Zhang C, Lu T, et al. Measurable residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049-4060.
  10. Rogers KA, Huang Y, Ruppert AS, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:3626-3637.
  11. Jain N, Keating M, Thompson P, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213-1219.
  12. Allan JN, Wierda WG, Siddiqi T, et al. Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: 26th Congress of the European Hematology Association; June 10-13, 2021. Abstract S147.
  13. Ghia P, Allan JN, Siddiqi T, et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the measurable residual disease (MRD) cohort of the phase 2 Captivate study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 68.
  14. Kater A, Owen C, Moreno C, et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. Presented at: 2021 European Hematology Association Annual Meeting; June 12, 2021. Abstract LB1902.
  15. Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease (MRD) outcomes after fixed duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for first-line treatment of CLL in elderly or unfit patients: the Glow study. Presented at: 63rd American Society of Hematology Annual Meeting; December 14, 2021. Abstract 70.
  16. Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the measurable residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853-3865.
  17. Soumerai JD, Mato AR, Carter J, et al. MRD-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated chronic lymphocytic leukemia. Presented at: 62nd American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 1307.